Tiempo real estimado
Otros sitios de cotización
|
Varia. Cinco días. | Varia. 1 de enero. | ||
2,185 USD | +7,11 % | +7,60 % | +13,14 % |
Resumen de negocios
Número de empleados: 224
Ventas por actividad
USD en millones | 2022 | Peso | 2023 | Peso | Delta |
---|---|---|---|---|---|
T-Cell Therapies
100,0
%
| 85 | 100,0 % | 0 | 100,0 % | -99,85 % |
Ventas por región
USD en millones | 2022 | Peso | 2023 | Peso | Delta |
---|---|---|---|---|---|
United States
100,0
%
| 85 | 100,0 % | 0 | 100,0 % | -99,85 % |
Directores
Directores | Puesto | Edad | Desde |
---|---|---|---|
Lynn Seely
CEO | Chief Executive Officer | 65 | 01/05/21 |
Charles Newton
DFI | Director of Finance/CFO | 53 | 01/02/21 |
Stephen Hill
COO | Chief Operating Officer | 53 | 01/06/19 |
Gary Lee
CTO | Chief Tech/Sci/R&D Officer | 47 | 31/01/22 |
Richard D. Goold
CTO | Chief Tech/Sci/R&D Officer | 64 | 01/04/19 |
Ellen Rose
IRC | Investor Relations Contact | - | 01/04/21 |
Matthew Lang
LAW | General Counsel | 48 | 05/07/23 |
Administradores
Administradores | Puesto | Edad | Desde |
---|---|---|---|
Lynn Seely
CEO | Chief Executive Officer | 65 | 01/05/21 |
Robert Nelsen
BRD | Director/Board Member | 60 | 01/09/18 |
Otis Brawley
BRD | Director/Board Member | 64 | 01/04/21 |
William Rieflin
BRD | Director/Board Member | 64 | 01/05/20 |
Richard Klausner
CEO | Chief Executive Officer | 72 | 01/06/18 |
Director/Board Member | 63 | 01/08/18 | |
Hans Bishop
BRD | Director/Board Member | 59 | 01/08/18 |
Elizabeth Nabel
BRD | Director/Board Member | 72 | 01/04/21 |
Clase de acciones
Vote | Quantity | Flotante | Autocontrol | Total Float | |
---|---|---|---|---|---|
Acción A | 1 | 254 096 311 | 203 841 664 ( 80,22 %) | 0 | 80,22 % |
Información de la empresa
Sector
Revisiones del BPA
Varia. 1 de ene. | Capi. | |
---|---|---|
+13,14 % | 518 M | |
+2,83 % | 108 mil M | |
+9,50 % | 104 mil M | |
+6,58 % | 23,66 mil M | |
-12,24 % | 22,1 mil M | |
-3,29 % | 19,71 mil M | |
-35,36 % | 18,2 mil M | |
-13,51 % | 16,19 mil M | |
+4,23 % | 13,72 mil M | |
+32,95 % | 12,22 mil M |
- Bolsa
- Acciones
- Acción Lyell Immunopharma, Inc. - Nasdaq
- Empresa Lyell Immunopharma, Inc.